Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$48.44 USD

48.44
11,207,997

+0.63 (1.32%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $48.50 +0.06 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Analysts Estimate Bristol-Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Signs That Your Trading Will Ruin Your Retirement - January 30, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Zacks Equity Research

Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Bristol-Myers Squibb (BMY) closed the most recent trading day at $64.81, moving +1.74% from the previous trading session.

Zacks Equity Research

Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study

by Zacks Equity Research

Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.

Zacks Equity Research

Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y

by Zacks Equity Research

Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.

Zacks Equity Research

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.

Zacks Equity Research

Roche Submits Application for Tecentriq-Avastin Combo in HCC

by Zacks Equity Research

Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

Zacks Equity Research

Here is Why Growth Investors Should Buy Bristol-Myers (BMY) Now

by Zacks Equity Research

Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q4 Earnings?

by Sweta Killa

With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.

Zacks Equity Research

Zacks.com featured highlights include: SNX, ICHR, TECD, NSIT and BMY

by Zacks Equity Research

Zacks.com featured highlights include: SNX, ICHR, TECD, NSIT and BMY

Zacks Equity Research

Roche's Urothelial Cancer Study on Tecentriq Disappoints

by Zacks Equity Research

Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.

Zacks Equity Research

Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.

Zacks Equity Research

J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children

by Zacks Equity Research

Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.

Zacks Equity Research

Want To Retire Early? Learn the Intelligent Investing Secret - January 24, 2020

by Zacks Equity Research

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

Zacks Equity Research

Bristol-Myers Squibb (BMY) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Bristol-Myers Squibb (BMY) closed at $67.43 in the latest trading session, marking no change from the prior day.

Zacks Equity Research

Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza

by Zacks Equity Research

Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.

Zacks Equity Research

The Extreme Risks of Trading Your Own Retirement Assets - January 22, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Sweta Killa headshot

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Sweta Killa

Smart Beta ETF report for EUSA

Zacks Equity Research

5 Stocks Near a 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for January 21st

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 21st.

Zacks Equity Research

Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

BMY or AZN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BMY vs. AZN: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Bristol-Myers Squibb (BMY) a Good Stock to Pick Now?

by Zacks Equity Research

Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

by Kinjel Shah

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

Zacks Equity Research

J&J Seeks Label Expansion for Spravato Nasal Spray in EU

by Zacks Equity Research

J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.